Regeneron Pharmaceuticals (REGN) Profit After Tax (2009 - 2026)

Regeneron Pharmaceuticals has reported Profit After Tax for 18 years, with the latest figure at $727.2 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 10.08% year-over-year to $727.2 million; the trailing twelve-month figure through Mar 2026 stood at $4.4 billion (down 1.69% YoY), and the FY2025 full-year result was $4.5 billion, up 2.09% from the prior year.
• Profit After Tax for Q1 2026 stood at $727.2 million, down from $844.6 million in the prior quarter.
• The five-year high for Profit After Tax was $1.5 billion in Q3 2025, with the low at $722.0 million in Q1 2024.
• Average Profit After Tax over 5 years is $1.1 billion, with a median of $973.5 million recorded in 2022.
• Year-over-year, Profit After Tax slumped 72.5% in 2022 and surged 47.9% in 2024.
• Tracing REGN's Profit After Tax over 5 years: stood at $1.2 billion in 2022, then decreased by 3.13% to $1.2 billion in 2023, then slipped by 20.86% to $917.7 million in 2024, then declined by 7.97% to $844.6 million in 2025, then decreased by 13.9% to $727.2 million in 2026.
• The last three Profit After Tax figures came in at $727.2 million (Q1 2026), $844.6 million (Q4 2025), and $1.5 billion (Q3 2025), per Business Quant data.

Peer Comparison